Powell Neil, Upton Mathew, Kent Bridie, Sandoe Jonathan, Tonkin-Crine Sarah
Department of Pharmacy, Royal Cornwall Hospital, Truro, UK
University of Plymouth, Plymouth, UK.
BMJ Open. 2025 Jul 30;15(7):e096452. doi: 10.1136/bmjopen-2024-096452.
To develop a behavioural intervention package to support non-allergist healthcare workers (HCWs) to remove incorrect penA records from medical and surgical adult inpatients. This paper describes the development of the penicillin allergy de-labelling (PADL) intervention and the implementation intervention that will support non-allergist-delivered PADL.
We combined evidence-based, theory-based and person-based approaches. Qualitative research with healthcare professionals and patients explored barriers and enablers to implementation of the proposed PADL pathway. Key intervention design objectives and the key features of the implementation intervention required to achieve each objective were then developed and captured as guiding principles. We produced a logic model, integrating the theoretical domains framework to identify the behavioural influences on PADL and the behaviour change wheel to show how the implementation intervention is hypothesised to address the target behaviours. The implementation intervention package was then reviewed by stakeholders and topic experts for further refinement and optimisation. Finally, we outline how the implementation intervention will be evaluated.
Single-centre District General Hospital in the SW England servicing a rural community of 575 000 people without local allergy services.
HCWs reported PADL needed to be structured, standardised, evidence based and supported by hospital approved guidelines with easy to access patient information leaflets, supported by a sustained programme of education and training with named PADL leaders and visible PADL champions. Patients wanted a good explanation of the benefits and risks of testing and the benefits of having their 'penA' record removed. The identified HCW target behaviours were: taking a penA allergy focused history and to risk assess the patient's penA history; to then either de-label the patient on history alone (direct de-label; DDL) or prescribe a direct oral challenge (DOC) dose; to perform baseline and post-test observations and counsel the patient on the risks of penA records and on the risks and the benefits of PADL. We identified barriers to target behaviours that we considered both important and modifiable, which included: lack of confidence in taking a penA focused history, PADL not viewed as a priority, low confidence with differentiating low-risk and high-risk penA histories, concerns about the safety of DOC, a requirement for senior support for nurses to deliver the observations and senior support for the other HCWs to deliver PADL, access to an expert for advice when required, a lack of PADL champions to promote PADL, and PADL not being supported by the organisation. The identified patient target behaviours were acceptance of the opportunity to be de-labelled via either DDL or DOC and willingness to take penicillin when prescribed. We developed intervention components to target the HCW and patient target behaviours which included: Education, expert advice made available from Infection specialists, a named PADL champion, hospital endorsed PADL guideline with necessary tools to enable PADL and patient information leaflets. The implementation intervention was further optimised through workshops with PADL researchers and stakeholders. The Consolidated Framework for Implementation Research outcome addendum was used to define both implementation intervention and PADL intervention outcomes.
We have developed a theory-based and stakeholder-developed implementation intervention to support inpatient PADL delivered by a multiprofession workforce. The intervention will be tested in a single hospital and scalability explored.
制定一套行为干预方案,以支持非过敏专科医护人员从成年内科和外科住院患者的病历中删除错误的青霉素过敏(penA)记录。本文描述了青霉素过敏去标签(PADL)干预措施的制定,以及将支持由非过敏专科人员实施PADL的实施干预措施。
我们结合了基于证据、基于理论和基于人的方法。对医护人员和患者进行的定性研究探讨了实施拟议的PADL途径的障碍和促进因素。然后制定了关键干预设计目标以及实现每个目标所需的实施干预措施的关键特征,并将其作为指导原则。我们构建了一个逻辑模型,整合了理论领域框架以识别对PADL的行为影响,并结合行为改变轮来展示实施干预措施如何被假定为能够解决目标行为。然后,利益相关者和主题专家对实施干预方案进行了审查,以进一步完善和优化。最后,我们概述了将如何评估实施干预措施。
位于英格兰西南部的一家单中心地区综合医院,服务于一个拥有57.5万人口的农村社区,当地没有过敏专科服务。
医护人员报告称,PADL需要结构化、标准化、基于证据,并得到医院批准的指南支持,同时要有易于获取的患者信息手册,并辅以由指定的PADL负责人和有影响力的PADL倡导者开展的持续教育和培训计划。患者希望能得到关于检测的益处和风险以及删除其“penA”记录的益处的详细解释。确定的医护人员目标行为包括:获取聚焦于penA过敏的病史并对患者的penA病史进行风险评估;然后要么仅根据病史对患者进行去标签(直接去标签;DDL),要么开出直接口服激发试验(DOC)剂量;进行基线和试验后观察,并就penA记录的风险以及PADL的风险和益处向患者提供咨询。我们确定了我们认为既重要又可改变的目标行为障碍,包括:对获取聚焦于penA的病史缺乏信心、不将PADL视为优先事项、区分低风险和高风险penA病史的信心不足、对DOC安全性的担忧、护士进行观察需要高级人员支持以及其他医护人员实施PADL需要高级人员支持、需要在必要时获得专家建议、缺乏PADL倡导者来推广PADL以及该组织不支持PADL。确定的患者目标行为是接受通过DDL或DOC进行去标签的机会,并愿意在开具青霉素处方时服用。我们制定了针对医护人员和患者目标行为的干预措施组成部分,包括:教育、由感染专家提供专家建议、指定一名PADL倡导者、医院认可的PADL指南以及实施PADL所需的必要工具和患者信息手册。通过与PADL研究人员和利益相关者举办的研讨会,进一步优化了实施干预措施。使用实施研究结果增编的综合框架来定义实施干预措施和PADL干预措施的结果。
我们制定了一种基于理论且由利益相关者共同制定的实施干预措施,以支持由多专业医护人员实施的住院患者PADL。该干预措施将在一家医院进行测试,并探索其可扩展性。